Patents Assigned to Boehringer Ingelheim International GmbH
  • Patent number: 11918596
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: March 5, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • Patent number: 11919903
    Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: March 5, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Sieger, Dirk Kemmer, Peter Kohlbauer, Thomas Nicola, Martin Renz
  • Patent number: 11911388
    Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: February 27, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Eva Ulrike Graefe-Mody, Thomas Klein, Michael Mark, Hans-Juergen Woerle
  • Patent number: 11911387
    Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: February 27, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Klein, Andreas Daiber, Odd-Erik Johansen, Michael Mark, Sanjaykumar Patel, Hans-Juergen Woerle
  • Patent number: 11891403
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: February 6, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Jens Willwacher
  • Patent number: 11884744
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: January 30, 2024
    Assignees: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Patent number: 11884652
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: January 30, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Martin Thomas Fleck, Jens Willwacher
  • Patent number: 11883580
    Abstract: A nebulizer for nebulizing a fluid from a cartridge and a cartridge for such a nebulizer is proposed. The cartridge comprises a container containing the fluid to be nebulized and is fluidically connected to the nebulizer by inserting a connecting element of the nebulizer for conveying the fluid out of the container. The cartridge is preferably adapted to sealingly receive the connecting element and can optionally comprise a membrane or sealing wall which seals the cartridge initially and is piercable or breakable by the connecting element upon insertion. The cartridge can further comprise an at least partially flexible and/or bendable tube for conveying the fluid out of the container. The tube is preferably wettable with the fluid and/or comprises an at least partially hydrophilic and/or polar surface. Further, the tube can at least partially be shaped as a helix.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 30, 2024
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephen Terence Dunne, Joachim Carl Herbert Eicher, Herbert Graessl, Andree Jung, Gilbert Wuttke
  • Patent number: 11884681
    Abstract: The present disclosure provides certain 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 30, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder
  • Patent number: 11878981
    Abstract: The present disclosure provides certain substituted 1,2,4-oxadiazole derivatives of the below formula (I) that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 23, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Georg Dahmann, Martin Thomas Fleck, Annekatrin Charlotte Heimann, Thorsten Oost
  • Patent number: 11866501
    Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: January 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Katharina Florin, Cynthia Hess Kenny, Sarah Kathleen Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir H. Voynov, Haiguang Xiao
  • Patent number: 11858921
    Abstract: The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 2, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Martin Thomas Fleck, Jens Willwacher
  • Patent number: 11851418
    Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein R, R1, A1, A2, L1, and L2 are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the compounds of formula (I) for treatment of diseases, which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: December 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Maude Giroud, Camilla Mayer, Holger Wagner, Dieter Wiedenmayer
  • Patent number: 11851495
    Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 26, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
  • Patent number: 11833166
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: December 5, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • Patent number: 11813312
    Abstract: The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Leo Thomas
  • Patent number: 11813266
    Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Franziska Elena Herrmann, Peter Nickolaus, Stefan Ludwig Michael Wollin
  • Patent number: 11813275
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
  • Patent number: 11814380
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Christiane Kofink, Heinz Stadtmueller, Tobias Wunberg, Marco Hans Hofmann, Anke Baum, Michael Gmachl, Dorothea Ingrid Rudolph, Fabio Savarese, Markus Ostermeier, Markus Frank, Annika Gille, Stefan Goepper, Marco Santagostino, Julian Wippich
  • Patent number: 11795147
    Abstract: The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: October 24, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kai Gerlach, Christian Eickmeier, Jan Magnus Kriegl, Lothar Kussmaul, Klaus Rudolf, Bernhard Schmid